Table 1 Baseline characteristics (N = 173)
| Â | Â | the diagnosis interval | Â | |
|---|---|---|---|---|
Characteristic | Total(N = 173) |  ≤ 6 months(N = 99) |  > 6 months(N = 74) | P Value |
Status, n (%) | ||||
 Living | 97(56.1) | 52(52.5) | 45(60.8) | 0.568 |
 Died | 35(20.2) | 22(22.2) | 13(17.6) |  |
 Unknown | 41(23.7) | 25(25.3) | 16(21.6) |  |
Gender, n (%) | ||||
 Male | 141(81.5) | 82(82.8) | 59(79.7) | 0.693 |
 Female | 32(18.5) | 17(17.2) | 15(20.3) |  |
Age, y | ||||
 Median (IQR), y | 64(58.5,69.5) | 65 (59,69) | 63(58,70) | 0.528 |
  < 65, n (%) | 89(51.4) | 46(46.5) | 43(58.1) | 0.130 |
  ≥ 65, n (%) | 84(48.6) | 53(53.5) | 31(41.9) |  |
Smoking, n (%) | ||||
 Yes | 97(56.1) | 54(54.5) | 43(58.1) | 0.726 |
 No | 49(28.3) | 29(29.3) | 20(27.0) |  |
 Unknown | 27(15.6) | 16(16.2) | 11(14.9) |  |
ECOG Performance | Â | Â | Â | 0.000 |
Status, n (%) | ||||
 0–2 | 133(76.9) | 66(49.6) | 67(90.5) |  |
 3–4 | 22(12.7) | 15(15.2) | 7(9.5) |  |
 Unknow | 18(10.4) | 18(18.2) | 0(0.0) |  |
Comorbidities, n (%) | ||||
 DM | 27(15.6) | 14(14.1) | 13(17.6) | 0.673 |
 HTN | 25(14.5) | 14(14.1) | 11(14.9) | 1.000 |
 COPD/Emphysema | 48(27.7) | 32(32.3) | 16(21.6) | 0.123 |
 CHD/Arrthythmia | 10(5.8) | 5(5.1) | 5(6.8) | 0.746 |
 Bronchiectasis | 11(6.4) | 6(6.1) | 5(6.8) | 1.000 |
 Liver disease | 6(3.5) | 3(3.0) | 3(4.1) | 1.000 |
 Stoke | 7(4) | 4(4.0) | 3(4.1) | 1.000 |
 Immunodeficiency | 3(1.7) | 3(3.0) | 0(0.0) | 0.261 |
 Other cancers | 5(2.9) | 3(3.0) | 2(2.7) | 1.000 |
Cancer type, n (%) | ||||
 SCLC | 12(6.9) | 8(8.1) | 4(5.4) | 0.017 |
 NSCLC | 159(91.9) | 91(91.9) | 68(91.9) |  |
 Adenocarcinoma | 93(53.8) | 46(46.5) | 47(63.5) |  |
 Squamous cell carcinoma | 55(31.8) | 40(40.4) | 15(20.3) |  |
 Undifferentiated | 11(6.4) | 5(5.1) | 11(14.9) |  |
 Unknown | 2(1.2) | 0(0.0) | 2(2.7) |  |
Stage, n (%) | ||||
 I | 50(28.9) | 27(27.3) | 23(31.1) | 0.332 |
 II | 8(4.6) | 4(4.0) | 4(5.4) |  |
 III | 33(19.1) | 20(20.2) | 13(17.6) |  |
 IV | 58(33.5) | 38(38.4) | 20(27.0) |  |
 Unknown | 24(13.9) | 10(10.1) | 14(18.9) |  |
Tumor location, n (%) | ||||
 Bilateral | 13(7.5) | 7(7.1) | 6(8.1) | 0.103 |
 Right | 86(49.7) | 56(56.6) | 30(40.5) |  |
 Left | 74(42.8) | 36(36.4) | 38(51.4) |  |
System involved, n (%) | ||||
 Pulmonary and extrapulmonary | 6(3.5) | 0(0.0) | 6(8.1) | 0.008 |
 Pulmonary only | 162(93.6) | 96(97.0) | 66(89.2) |  |
 Extrapulmonary only | 5(2.9) | 3(3.0) | 2(2.7) |  |
 Cavity, n (%) | 47(27.2) | 27(27.3) | 20(27.0) | 1.000 |
 Retreatment TB, n (%) | 17(9.8) | 8(8.1) | 9(12.2) | 0.442 |
Treatment, n (%) | ||||
 Surgery | 68(39.3) | 24(24.2) | 44(59.5) | 0.000 |
 Chemotherapy | 50(28.9) | 22(22.2) | 28(37.8) | 0.011 |
 Radiation | 20(11.6) | 8(8.1) | 12(59.5) | 0.118 |
 targeted therapy | 15(8.7) | 7(7.1) | 8(10.8) | 0.559 |
 Anti-PD-(L)1 therapy | 7 (4) | 4(4.0) | 3(4.1) | 0.878 |
 Anti-TB treatment | 168 (97.1) | 96 (97.0) | 72 (97.3) | 0.396 |
CRP(mg/L),n (%) | ||||
  < 10 | 49(28.3) | 29(29.3) | 20(27.0) | 0.641 |
 10–50 | 29(16.8) | 14(14.1) | 15(20.3) |  |
  > 50 | 26(15.0) | 14(14.1) | 12(16.2) |  |
 Unknown | 69(39.9) | 42(42.4) | 27(36.5) |  |
IL-1β, n (%) | ||||
 normal | 48(27.7) | 25(25.3) | 23(31.1) | 0.692 |
 Higher than normal | 14(8.1) | 8(8.1) | 6(8.1) |  |
 unknown | 111(64.2) | 66(66.7) | 45(60.8) |  |
IL-2R, n (%) | ||||
 Normal | 30(17.3) | 18(18.2) | 12(16.2) | 0.437 |
 Higher than normal | 32(18.5) | 15(15.2) | 17(23.0) |  |
 unknown | 111(64.2) | 66(66.7) | 45(60.8) |  |
IL-6, n (%) | ||||
 normal | 16(9.2) | 9(9.1) | 7(9.5) | 0.762 |
 Higher than normal | 46(26.6) | 24(24.2) | 22(29.7) |  |
 unknown | 111(64.2) | 66(66.7) | 45(60.8) |  |
TNF-α, n (%) | ||||
 Normal | 14(8.1) | 6(6.1) | 8(10.8) | 0.531 |
 Higher than normal | 42(24.3) | 25(25.3) | 17(23.0) |  |
 unknown | 117(67.6) | 68(68.7) | 49(66.2) |  |
IGRA, n (%) | ||||
 negative | 17(9.8) | 11(11.1) | 6(8.1) | 0.766 |
 positive | 127(73.4) | 71(71.7) | 56(75.7) |  |
 unknown | 29(16.8) | 17(17.2) | 12(16.2) |  |
 SAA(IQR), mg/L | 11(6.3,86.3) | 7.3(3.2,20.9) | 14.2(8.5,84.1) | 0.364 |
 ESR(IQR), mm/h | 50(25,81.5) | 36(24,68) | 54(15,71) | 0.304 |
 Lymphocyte count (SD) *10 ~ 9 | 1.3(0.6) | 1.3(0.5) | 1.2(0.6) | 0.714 |
 CD4 + /CD8 + T-cell ratio (IQR)*10 ~ 9 | 2(1.3,2.9) | 2.2(1.3,3.2) | 2(1.5,2.4) | 0.382 |
 Survival time (IQR), M | 21(9,49.5) | 14(11,19) | 29(8.5,62) | 0.000 |